{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:32:41Z","timestamp":1773289961341,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,29]],"date-time":"2008-01-29T00:00:00Z","timestamp":1201564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>TP53<\/jats:italic> is one of major tumour suppressor genes being essential in preservation of genome integrity. Two very common polymorphisms have been demonstrated to contribute to cancer susceptibility and tumour behaviour. The purpose of this study was to evaluate the role of <jats:italic>Arg72Pro<\/jats:italic> and <jats:italic>PIN3 Ins16bp<\/jats:italic> polymorphisms in <jats:italic>TP53<\/jats:italic> gene as genetic susceptibility and predictive markers to breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analysed DNA samples from 264 breast cancer patients and 440 controls, for <jats:italic>TP53 Arg72Pro<\/jats:italic> and <jats:italic>PIN3 Ins16bp<\/jats:italic> polymorphisms using PCR-RFLP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We observed that women with <jats:italic>A2A2<\/jats:italic> genotype have increased risk for developing breast cancer, either in women with or without familial history (FH) of the disease (OR = 4.40, 95% CI 1.60\u201312.0; p = 0.004; OR = 3.88, 95% CI 1.18\u201312.8; p = 0.026, respectively). In haplotype analysis, statistically significant differences were found between <jats:italic>TP53 Arg-A2<\/jats:italic> haplotype frequencies and familial breast cancer cases and the respective control group (OR = 2.10, 95% CI 1.08\u20134.06; p = 0.028). Furthermore, both <jats:italic>TP53<\/jats:italic> polymorphisms are associated with higher incidence of lymph node metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings suggest <jats:italic>TP53 PIN3 Ins16bp<\/jats:italic> polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer. Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph node metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-8-32","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T07:13:37Z","timestamp":1201677217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer"],"prefix":"10.1186","volume":"8","author":[{"given":"Sandra","family":"Costa","sequence":"first","affiliation":[]},{"given":"Daniela","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Cameselle-Teijeiro","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,1,29]]},"reference":[{"key":"970_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1289\/ehp.02110s1119","volume":"110 Suppl 1","author":"LS DeBruin","year":"2002","unstructured":"DeBruin LS, Josephy PD: Perspectives on the chemical etiology of breast cancer. Environ Health Perspect. 2002, 110 Suppl 1: 119-128.","journal-title":"Environ Health Perspect"},{"key":"970_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1582-4934.2005.tb00350.x","volume":"9","author":"RG Dumitrescu","year":"2005","unstructured":"Dumitrescu RG, Cotarla I: Understanding breast cancer risk -- where do we stand in 2005?. J Cell Mol Med. 2005, 9: 208-221. 10.1111\/j.1582-4934.2005.tb00350.x.","journal-title":"J Cell Mol Med"},{"key":"970_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107327480501200210","volume":"12","author":"V Dapic","year":"2005","unstructured":"Dapic V, Carvalho MA, Monteiro AN: Breast cancer susceptibility and the DNA damage response. Cancer Control. 2005, 12: 127-136.","journal-title":"Cancer Control"},{"key":"970_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, .: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086\/301749.","journal-title":"Am J Hum Genet"},{"key":"970_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJM200007133430201","volume":"343","author":"P Lichtenstein","year":"2000","unstructured":"Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000, 343: 78-85. 10.1056\/NEJM200007133430201.","journal-title":"N Engl J Med"},{"key":"970_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2004.07.002","volume":"52","author":"A Feki","year":"2004","unstructured":"Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 2004, 52: 103-116. 10.1016\/j.critrevonc.2004.07.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"970_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/humu.10173","volume":"21","author":"M Gasco","year":"2003","unstructured":"Gasco M, Yulug IG, Crook T: TP53 mutations in familial breast cancer: functional aspects. Hum Mutat. 2003, 21: 301-306. 10.1002\/humu.10173.","journal-title":"Hum Mutat"},{"key":"970_CR8","first-page":"6643","volume":"63","author":"M Olivier","year":"2003","unstructured":"Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63: 6643-6650.","journal-title":"Cancer Res"},{"key":"970_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng747","volume":"29","author":"J Jonkers","year":"2001","unstructured":"Jonkers J, Meuwissen R, van der GH, Peterse H, van , Berns A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001, 29: 418-425. 10.1038\/ng747.","journal-title":"Nat Genet"},{"key":"970_CR10","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1038\/sj.onc.1206439","volume":"22","author":"PP Ongusaha","year":"2003","unstructured":"Ongusaha PP, Ouchi T, Kim KT, Nytko E, Kwak JC, Duda RB, Deng CX, Lee SW: BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest. Oncogene. 2003, 22: 3749-3758. 10.1038\/sj.onc.1206439.","journal-title":"Oncogene"},{"key":"970_CR11","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1158\/1078-0432.CCR-05-0507","volume":"11","author":"Y Xu","year":"2005","unstructured":"Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005, 11: 7328-7333. 10.1158\/1078-0432.CCR-05-0507.","journal-title":"Clin Cancer Res"},{"key":"970_CR12","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-05-0173","volume":"11","author":"J Tommiska","year":"2005","unstructured":"Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von SK, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005, 11: 5098-5103. 10.1158\/1078-0432.CCR-05-0173.","journal-title":"Clin Cancer Res"},{"key":"970_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/path.1529","volume":"202","author":"R Medeiros","year":"2004","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C: Linkage of angiotensin I-converting enzyme gene insertion\/deletion polymorphism to the progression of human prostate cancer. J Pathol. 2004, 202: 330-335. 10.1002\/path.1529.","journal-title":"J Pathol"},{"key":"970_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-4608(02)00660-X","volume":"141","author":"R Medeiros","year":"2003","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lopees C: Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet. 2003, 141: 91-96. 10.1016\/S0165-4608(02)00660-X.","journal-title":"Cancer Genet Cytogenet"},{"key":"970_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.cej.0000130015.91525.c7","volume":"13","author":"D Pinto","year":"2004","unstructured":"Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C, Medeiros R: HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev. 2004, 13: 177-181. 10.1097\/01.cej.0000130015.91525.c7.","journal-title":"Eur J Cancer Prev"},{"key":"970_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ejca.2006.01.015","volume":"42","author":"AM Santos","year":"2006","unstructured":"Santos AM, Sousa H, Pinto D, Portela C, Pereira D, Catarino R, Duarte I, Lopes C, Medeiros R: Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer. 2006, 42: 958-963. 10.1016\/j.ejca.2006.01.015.","journal-title":"Eur J Cancer"},{"key":"970_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/humu.10081","volume":"19","author":"M Olivier","year":"2002","unstructured":"Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002, 19: 607-614. 10.1002\/humu.10081.","journal-title":"Hum Mutat"},{"key":"970_CR18","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/sj.onc.1209367","volume":"25","author":"EC Pietsch","year":"2006","unstructured":"Pietsch EC, Humbey O, Murphy ME: Polymorphisms in the p53 pathway. Oncogene. 2006, 25: 1602-1611. 10.1038\/sj.onc.1209367.","journal-title":"Oncogene"},{"key":"970_CR19","doi-asserted-by":"crossref","unstructured":"Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997, 349: 1505-1510. 10.1016\/S0140-6736(96)10109-4.","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"970_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2565(02)71047-3","volume":"202","author":"F Duarte","year":"2002","unstructured":"Duarte F, Cameselle-Teijeiro JF, Soares R, Seixas C, Cortizo-Torres ME, Perez-Villanueva J, Schmitt FC: [Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]. Rev Clin Esp. 2002, 202: 259-263.","journal-title":"Rev Clin Esp"},{"key":"970_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1086\/375140","volume":"72","author":"LP Zhao","year":"2003","unstructured":"Zhao LP, Li LL, Khalid N: A method for assessing disease associations with SNP haplotypes and environmental variables in case-control. Am J Hum Genet. 2003, 72: 1231-1250. 10.1086\/375140.","journal-title":"Am J Hum Genet"},{"key":"970_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038\/35021093.","journal-title":"Nature"},{"key":"970_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/pros.10348","volume":"58","author":"R Medeiros","year":"2004","unstructured":"Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, Morais A, Oliveira J, Lopes C: Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate. 2004, 58: 414-420. 10.1002\/pros.10348.","journal-title":"Prostate"},{"key":"970_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/pros.20241","volume":"64","author":"S Costa","year":"2005","unstructured":"Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C, Medeiros R: Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate. 2005, 64: 246-252. 10.1002\/pros.20241.","journal-title":"Prostate"},{"key":"970_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.canlet.2006.03.014","volume":"246","author":"S Costa","year":"2006","unstructured":"Costa S, Pinto D, Pereira D, Vasconcelos A, fonso-Lopes C, Osorio T, Lopes C, Medeiros R: Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer. Cancer Lett. 2006, 246: 324-330. 10.1016\/j.canlet.2006.03.014.","journal-title":"Cancer Lett"},{"key":"970_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-006-9205-0","volume":"99","author":"MM Gaudet","year":"2006","unstructured":"Gaudet MM, Bensen JT, Schroeder J, Olshan AF, Terry MB, Eng SM, Teitelbaum SL, Britton JA, Lehman TA, Neugut AI, Ambrosone CB, Santella RM, Gammon MD: Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York. Breast Cancer Res Treat. 2006, 99: 235-240. 10.1007\/s10549-006-9205-0.","journal-title":"Breast Cancer Res Treat"},{"key":"970_CR27","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1055-9965.EPI-05-0078","volume":"14","author":"A Shin","year":"2005","unstructured":"Shin A, Shu XO, Cai Q, Gao YT, Zheng W: Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1567-1570. 10.1158\/1055-9965.EPI-05-0078.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"970_CR28","first-page":"771","volume":"4","author":"RM Dufloth","year":"2005","unstructured":"Dufloth RM, Costa S, Schmitt F, Zeferino LC: DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet Mol Res. 2005, 4: 771-782.","journal-title":"Genet Mol Res"},{"key":"970_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1055-9965.EPI-04-0330","volume":"14","author":"KM Lee","year":"2005","unstructured":"Lee KM, Choi JY, Park SK, Chung HW, Ahn B, Yoo KY, Han W, Noh DY, Ahn SH, Kim H, Wei Q, Kang D: Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005, 14: 821-825. 10.1158\/1055-9965.EPI-04-0330.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"970_CR30","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1038\/sj.onc.1209405","volume":"25","author":"M Siddique","year":"2006","unstructured":"Siddique M, Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006, 25: 3489-3500. 10.1038\/sj.onc.1209405.","journal-title":"Oncogene"},{"key":"970_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ijc.11548","volume":"108","author":"D Pim","year":"2004","unstructured":"Pim D, Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004, 108: 196-199. 10.1002\/ijc.11548.","journal-title":"Int J Cancer"},{"key":"970_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, Della PAC, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003, 33: 357-365. 10.1038\/ng1093.","journal-title":"Nat Genet"},{"key":"970_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00008571-200204000-00012","volume":"12","author":"S Wang-Gohrke","year":"2002","unstructured":"Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002, 12: 269-272. 10.1097\/00008571-200204000-00012.","journal-title":"Pharmacogenetics"},{"key":"970_CR34","first-page":"228","volume-title":"Human Genetics","author":"R Lewis","year":"2001","unstructured":"Lewis R: Human Genetics. 2001, New York, McGraw-Hill, 12: 228-232. 4","edition":"4"},{"key":"970_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1196\/annals.1299.137","volume":"1010","author":"I Mabrouk","year":"2003","unstructured":"Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A: No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003, 1010: 764-770. 10.1196\/annals.1299.137.","journal-title":"Ann N Y Acad Sci"},{"key":"970_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ijc.10834","volume":"103","author":"EN Suspitsin","year":"2003","unstructured":"Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN: Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 2003, 103: 431-433. 10.1002\/ijc.10834.","journal-title":"Int J Cancer"},{"key":"970_CR37","first-page":"4860","volume":"9","author":"M Bonafe","year":"2003","unstructured":"Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C: Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine\/Proline Heterozygous Breast Cancer Patients. Clin Cancer Res. 2003, 9: 4860-4864.","journal-title":"Clin Cancer Res"},{"key":"970_CR38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6602451","volume":"92","author":"T Ohayon","year":"2005","unstructured":"Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman MT, Eisenberg BS, Friedman E: The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 2005, 92: 1144-1148. 10.1038\/sj.bjc.6602451.","journal-title":"Br J Cancer"},{"key":"970_CR39","first-page":"711","volume":"10","author":"N Buyru","year":"2003","unstructured":"Buyru N, Tigli H, Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003, 10: 711-714.","journal-title":"Oncol Rep"},{"key":"970_CR40","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1128\/MCB.19.2.1092","volume":"19","author":"M Thomas","year":"1999","unstructured":"Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999, 19: 1092-1100.","journal-title":"Mol Cell Biol"},{"key":"970_CR41","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1136\/jmg.40.4.e34","volume":"40","author":"AM Martin","year":"2003","unstructured":"Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL: Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?. J Med Genet. 2003, 40: e34-10.1136\/jmg.40.4.e34.","journal-title":"J Med Genet"},{"key":"970_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/humu.20283","volume":"27","author":"A Osorio","year":"2006","unstructured":"Osorio A, Martinez-Delgado B, Pollan M, Cuadros M, Urioste M, Torrenteras C, Melchor L, Diez O, de la HM, Velasco E, Gonzalez-Sarmiento R, Caldes T, Alonso C, Benitez J: A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat. 2006, 27: 242-248. 10.1002\/humu.20283.","journal-title":"Hum Mutat"},{"key":"970_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrm1546","volume":"6","author":"S Sengupta","year":"2005","unstructured":"Sengupta S, Harris CC: p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 2005, 6: 44-55. 10.1038\/nrm1546.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"970_CR44","first-page":"105","volume":"6","author":"A Weston","year":"1997","unstructured":"Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS: p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev. 1997, 6: 105-112.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"970_CR45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0959-437X(94)90066-3","volume":"4","author":"JS Mattick","year":"1994","unstructured":"Mattick JS: Introns: evolution and function. Curr Opin Genet Dev. 1994, 4: 823-831. 10.1016\/0959-437X(94)90066-3.","journal-title":"Curr Opin Genet Dev"},{"key":"970_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nrg1321","volume":"5","author":"JS Mattick","year":"2004","unstructured":"Mattick JS: Rna Regulation: a new genetics?. Nat Rev Genet. 2004, 5: 316-10.1038\/nrg1321.","journal-title":"Nat Rev Genet"},{"key":"970_CR47","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.onc.1207305","volume":"23","author":"F Gemignani","year":"2004","unstructured":"Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F: A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004, 23: 1954-1956. 10.1038\/sj.onc.1207305.","journal-title":"Oncogene"},{"key":"970_CR48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jnci\/94.9.681","volume":"94","author":"X Wu","year":"2002","unstructured":"Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR: p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst. 2002, 94: 681-690.","journal-title":"J Natl Cancer Inst"},{"key":"970_CR49","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/carcin\/16.9.2233","volume":"16","author":"R Birgander","year":"1995","unstructured":"Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L: P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995, 16: 2233-2236. 10.1093\/carcin\/16.9.2233.","journal-title":"Carcinogenesis"},{"key":"970_CR50","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/carcin\/17.6.1313","volume":"17","author":"A Sjalander","year":"1996","unstructured":"Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996, 17: 1313-1316. 10.1093\/carcin\/17.6.1313.","journal-title":"Carcinogenesis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-32\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:22:14Z","timestamp":1630462934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,29]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-32","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,29]]},"assertion":[{"value":"7 May 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"32"}}